ResMed announced it will acquire Noctrix Health, a developer of the FDA de‑novo classified NTX100 Tonic Motor Activation system for moderate‑to‑severe restless‑leg syndrome, for $340 million in cash and stock. The deal adds an estimated $24 million in annual revenue and is expected to close on June 1, 2026, bringing Noctrix into ResMed’s Americas devices segment.
The acquisition expands ResMed’s sleep‑health portfolio into a new therapeutic area that overlaps with its existing sleep‑apnea products. Restless‑leg syndrome is the third most prevalent sleep disorder worldwide, and a 10‑30 % comorbidity with obstructive sleep apnea creates cross‑selling opportunities. "RLS has meaningful overlap with our core market of obstructive sleep apnea. RLS treatments from Noctrix are noninvasive, clinically proven and drug free, just like our CPAP, APAP and bi‑level therapies. RLS prescriptions are written predominantly by sleep physicians, and the flagship product flows through the same HME/DME delivery channel." – Mick Farrell.
The transaction will deepen ResMed’s ecosystem and support margin expansion. CFO Brett Sandercock noted that the Noctrix platform is expected to contribute gross margins in the 62 %‑63 % range for fiscal 2026, compared with ResMed’s overall margin of 61 % in the same period. The acquisition is also projected to be slightly EPS dilutive in the short term, with a $0.02 reduction in non‑GAAP EPS for Q4 FY2026, but the added revenue and margin profile should offset the impact over the next few quarters.
Management emphasized that Noctrix’s technology can be scaled faster than any other competitor. "We can scale it faster than anyone." – Mick Farrell. The deal positions ResMed to capture a larger share of the growing RLS market, which serves approximately 17 million people in the United States alone.
The transaction is expected to close on June 1, 2026, after regulatory and shareholder approvals. Noctrix will be reported within ResMed’s Americas devices segment, and the company will integrate the technology into its existing product lines to accelerate market penetration.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.